<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04102774</url>
  </required_header>
  <id_info>
    <org_study_id>AIRVO-BX</org_study_id>
    <nct_id>NCT04102774</nct_id>
  </id_info>
  <brief_title>Effect of AIRVO Heated Humidification in Bronchiectasis</brief_title>
  <acronym>AIRVO-BX</acronym>
  <official_title>Multicenter, Pragmatic, Randomized, Controlled Trial to Assess the Efficacy and Safety of Nocturnal Humidification Therapy in Patients With Bronchiectasis: the AIRVO-BX Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Azienda Ospedaliera San Gerardo di Monza</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ASST Fatebenefratelli Sacco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione IRCCS Policlinico San Matteo di Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Maggiore Di Trieste</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria di Modena</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Policlinico Universitario Agostino Gemelli IRCCS</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Ferrara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero, Universitaria Pisana</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>IRCCS Azienda Ospedaliero-Universitaria di Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Paolo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universita degli Studi di Catania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera di Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliero-Universitaria di Parma</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Foggia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Monaldi Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Don Carlo Gnocchi Onlus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale San Donato</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate whether long-term heated humidification therapy&#xD;
      (AIRVO) administrated for 1 year over-night on top of standard therapy can reduce the number&#xD;
      of exacerbations in adults with non-cystic fibrosis bronchiectasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Bronchiectasis is a chronic condition characterized by an abnormal widened airways, mucus&#xD;
      retention, cough, daily sputum, and frequent respiratory infections. The management of&#xD;
      bronchiectasis includes prevention of exacerbations and lung infections along with airway&#xD;
      clearance techniques.&#xD;
&#xD;
      Mucus composition and hydration are crucial to allow mucus transport along airways during&#xD;
      respiratory physiotherapy.&#xD;
&#xD;
      Previous studies showed that long term humidification therapy increased airway clearance&#xD;
      (Hasani et al. 2008) and reduced the number of exacerbations in patients with both&#xD;
      bronchiectasis and Chronic Obstructive Pulmonary Disease (COPD) (Rea et al. 2010). myAIRVO2&#xD;
      system can deliver high-flow warm and humidified gases through a nasal cannula.&#xD;
&#xD;
      The aim of the present study to assess the effect of long-term use over-night of myAIRVO2&#xD;
      warm humidification in adults with bronchiectasis who experience at least 3&#xD;
      exacerbations/year still with optimized clinical and respiratory therapies.&#xD;
&#xD;
      In addition to their usual therapy, the treatment group will receive a myAIRVO2 humidifier at&#xD;
      home deliver every day for one year over-night.&#xD;
&#xD;
      The gas flow setting will be set between 20 and 30 l/min based on patient preference,&#xD;
      temperature will be 37°C and, for patients already in long-term oxygen therapy, FiO2 will be&#xD;
      regulated according to patient's prescription.&#xD;
&#xD;
      The control group will continue to receive standard therapy for bronchiectasis according to&#xD;
      international guidelines.&#xD;
&#xD;
      Patients will be screened during outpatient visits and, if they meet study criteria, they&#xD;
      will be enrolled in the study. Once enrolled in the study, patients will be followed up every&#xD;
      3 months with 4 consecutive outpatient visits. The following endpoints will be assessed:&#xD;
      exacerbations frequency, quality of life, pulmonary function and, for patients enrolled in&#xD;
      the treatment group, myAIRVO2 use, and comfort.&#xD;
&#xD;
      Statistical analysis will be performed by Prof. Giovanni Sotgiu (University of Sassari -&#xD;
      Italy).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2019</start_date>
  <completion_date type="Anticipated">May 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>All the patients meeting inclusion/esclusion criteria will be enrolled and randomized into one of the two arms. The control arm will receive standard therapy. The treatment arm will receive standard therapy + long-term humidification therapy with myAIRVO2 at home overnight.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pulmonary exacerbations</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Number of pulmonary exacerbations</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pulmonary exacerbations requiring hospitalization</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Number of pulmonary exacerbations requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first pulmonary exacerbation</measure>
    <time_frame>Up to 12 months. From date of randomization until the date of first documented pulmonary exacerbation</time_frame>
    <description>Time occurring from the randomization to the first pulmonary exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hospitalization for exacerbation</measure>
    <time_frame>Up to 12 months.From date of randomization until the date of first documented hospitalization for pulmonary exacerbation</time_frame>
    <description>Time occurring from the randomization to the first exacerbation requiring hospitalization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days with symptoms of exacerbation</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Number of days the patient showed symptoms of exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days of anibiotic treatment for exacerbation</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Number of days of antibiotic treatment for exacerbation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients requiring de novo oxygen therapy</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Number of patients starting de novo oxygen treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality-of-Life-Bronchiectasis Questionnaire, that measures health-related quality of life</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>We will measure changes in the score of Quality-of-Life-Bronchiectasis Questionnaire (QoL-B) completed by enrolled subjects at baseline and after 6 and 12 months.&#xD;
This disease-related questionnaire does not generate a total score, but a specific score for 8 different components: physical functioning domain, role functioning domain, vitality domain, emotional domain, social functioning domain, treatment burden domain, health perception domain and respiratory symptoms domain.&#xD;
For each component the scale range is 0 - 100, where higher scores correspond to better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St.George Respiratory Questionnaire, that measures health-related quality of life</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>We will measure changes in the score of St.George Respiratory Questionnaire (SGRQ) completed by enrolled subjects at baseline and after 6 and 12 months.&#xD;
This questionnaire is structured into 3 main components: symptoms, activity and impacts.&#xD;
Scale range is 0-100, where lower scores correspond to the better health status.&#xD;
Each questionnaire response has a unique empirically derived &quot;weight&quot;.&#xD;
Each component of the questionnaire is scored separately in three steps:&#xD;
i. The weights for all items with a positive responses are summed. ii The weights for missed items are deducted from the maximum possible weight for each component. The weights for all missed items are deducted from the maximum possible weight for the Total score.&#xD;
iii. The score is calculated by dividing the summed weights by the adjusted maximum possible weight for that component and expressing the result as a percentage The Total score is calculated in similar way.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bronchiectasis Health Questionnaire, that measures health-related quality of life</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>We will measure changes in the score of Bronchiectasis Health Questionnaire (BHQ) completed by enrolled subjects at baseline and after 6 and 12 months.&#xD;
This disease-specific questionnaire generates a single total score. The maximum score is 79,42 and corresponds to a better health status, the minimum score is 26,77 and corresponds to a worse health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leicester Cough Questionnaire, that measures health-related quality of life</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>We will measure changes in the score of Leicester Cough Questionnaire (LCQ) completed by enrolled subjects at baseline and after 6 and 12 months.&#xD;
This questionnaire consists of 19 items with a 7 point response scale. Each item is developed to assess impacts of cough on three main domains: physical, psychological and social.&#xD;
Scores are calculated as a mean of scores obtained for items of each domain (range 1 to 7).&#xD;
Total score is calculated by adding every single domain score (range 3-21). For both total and domains' scores higher values indicates better health status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function as change in Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>Change in FEV1, measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulmonary function as change in Forced Vital Capacity (FVC)</measure>
    <time_frame>baseline - 6 and 12 months</time_frame>
    <description>Change in FVC, measured by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>All-cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality due to respiratory causes</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Mortality rate caused by respiratory disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Frequency and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-use of AIRVO therapy</measure>
    <time_frame>baseline - 12 months</time_frame>
    <description>Frequency of permanent or temporary AIRVO therapy stopping</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Bronchiectasis Adult</condition>
  <arm_group>
    <arm_group_label>myAIRVO2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a myAIRVO2 at home over-night with humidifier on top of standard therapy for bronchiectasis according to international guidelines (ERS 2017).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive standard therapy for bronchiectasis according to international guidelines (ERS 2017).</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Over-night treatment with myAIRVO2</intervention_name>
    <description>Gas flow will be set between 20 and 30 l/min, according to patient's comfort, and administrated via nasal canula.&#xD;
Temperature will be set at 37°C. If the patient was already in nocturnal oxygen therapy FiO2 will be set according to the prescription.</description>
    <arm_group_label>myAIRVO2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Radiological evidence of bronchiectasis evaluated through a CT-scan of the chest&#xD;
&#xD;
          -  Daily sputum production&#xD;
&#xD;
          -  Presence of at least 3 exacerbations requiring antibiotic therapy during the 12 months&#xD;
             prior randomization&#xD;
&#xD;
          -  Absence of exacerbations during the 28 days prior randomization&#xD;
&#xD;
          -  Having the bronchiectasis management/therapy optimized according to international&#xD;
             guidelines (ERS Polverino 2017) during the 12 months preceding randomization and no&#xD;
             changes in therapy occurred during the 28 days prior randomization&#xD;
&#xD;
          -  Airways clearance physiotherapy optimized and unchanged during the 12 months prior&#xD;
             randomization&#xD;
&#xD;
          -  Being able to use myAIRVO2 (assessed by study investigators)&#xD;
&#xD;
          -  Given consent to inclusion in the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Being enrolled in other intervention trials during the 12 months prior randomization&#xD;
&#xD;
          -  COPD or asthma recognized as main diseases by the study investigator&#xD;
&#xD;
          -  Active smoker or ex-smoker who underwent smoking cessation during the 4 weeks prior&#xD;
             randomization&#xD;
&#xD;
          -  Any other disease or medical condition diagnosed during the 3 months prior&#xD;
             randomization which can affect patients' safety&#xD;
&#xD;
          -  Long-term treatment with non-invasive ventilation (NIV)&#xD;
&#xD;
          -  Long-term night treatment with continuous positive airway pressure (CPAP)&#xD;
&#xD;
          -  Tracheostomy&#xD;
&#xD;
          -  Major haemoptysis (more than 300ml or requiring embolization or requiring blood&#xD;
             transfusion) during the 6 weeks prior randomization&#xD;
&#xD;
          -  Cystic fibrosis&#xD;
&#xD;
          -  Traction bronchiectasis in the context of pulmonary fibrosis&#xD;
&#xD;
          -  Lung cancer in the last 5 years&#xD;
&#xD;
          -  Use of drugs that can modify mucus liquid content including mannitol, Hypertoinc&#xD;
             saline, DNase, NAC&#xD;
&#xD;
          -  Changes in the rehabilitation/respiratory therapy program during the 28 days before&#xD;
             randomization&#xD;
&#xD;
          -  Pregnant and brest-feeding women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Aliberti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stefano Aliberti, MD</last_name>
    <phone>0039255033789</phone>
    <email>stefano.aliberti@unimi.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martina Santambrogio, PhD</last_name>
    <phone>00393393838807</phone>
    <email>martina.santambrogio@policlinico.mi.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Unità Operativa di Riabilitazione Pneumologica, Istituti Clinici Scientifici Maugeri SpA - Società Benefit , Istituto Scientifico di Lumezzane</name>
      <address>
        <city>Lumezzane</city>
        <state>Brescia</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michele Vitacca, MD</last_name>
      <email>michele.vitacca@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Divisione di Pneumologia riabilitativa e Laboratorio di Citoimmunopatologia, Biochimica dell'apparato respiratorio, Istituti Clinici Scientifici Maugeri SpA - Società Benefit, Istituto di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Veruno</city>
        <state>Novara</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno Balbi, MD</last_name>
      <email>bruno.balbi@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Università degli Studi dell'Insubria e Istituti Clinici Scientifici Maugeri SpA - Società Benefit</name>
      <address>
        <city>Tradate</city>
        <state>Varese</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Spanevello, MD</last_name>
      <email>antonio.spanevello@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C Pneumologia e UTIP, Ospedale S. Donato</name>
      <address>
        <city>Arezzo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raffaele Scala, MD</last_name>
      <email>raffaele_scala@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Specialistica Diagnostica e Sperimentale, Alma Mater Studiorum, Università degli Studi di Bologna</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Nava, MD</last_name>
      <email>stefano.nava@aosp.bo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale, U.O. di Fisiopatologia Respiratoria, Allergologia e Immunologia polmonare, Università degli Studi di Catania</name>
      <address>
        <city>Catania</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nunzio Crimi, MD</last_name>
      <email>crimi@unict.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze Mediche e Chirurgiche, Settore Malattie dell'Apparato Respiratorio, Università degli Studi di Foggia</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Donato Lacedonia, MD</last_name>
      <email>donatolacedonia@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Scienze biomediche e cliniche &quot;Luigi Sacco&quot; DIBIC, Università degli Studi di Milano, U.O.C Pneumologia, Ospedale L. Sacco - ASST Fatebenfratelli Sacco</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierachille Santus, PhD</last_name>
      <email>pierachille.santus@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Riabilitazione pneumologica, IRCCS Santa Maria nascente - fondazione don Gnocchi</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo Banfi, MD</last_name>
      <email>pabanfi@dongnocchi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C. Pneumologia, ASST- Santi Paolo e Carlo, Ospedale San Paolo, Dipartimento di Scienze della Salute, Università degli Studi di Milano</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stefano Centanni, MD</last_name>
      <email>stefano.centanni@unimi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Pathophysiology and Transplantation, University of Milan Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano Aliberti, MD</last_name>
      <phone>0039255033789</phone>
      <email>stefano.aliberti@unimi.it</email>
    </contact>
    <contact_backup>
      <last_name>Martina Santambrogio, PhD</last_name>
      <phone>00393393838807</phone>
      <email>martina.santambrogio@policlinico.mi.it</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Malattie dell'apparato Respiratorio e Centro delle Malattie Rare del Polmone, Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università degli Studi di Modena e Reggio Emilia, Azienda Ospedaliero-Unive</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Enrico Clini, MD</last_name>
      <email>enrico.clini@unimore.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Pneumologia Ospedale San Gerardo ASST Monza</name>
      <address>
        <city>Monza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Paola Faverio, MD</last_name>
      <email>paola.faverio@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O.C. Pneumologia SUN, Ospedale Monaldi</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cecilia Calabrese, MD</last_name>
      <email>ceciliacalabrese123@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Fisiopatologia Respiratoria, Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andrea Vianello, MD</last_name>
      <email>andrea.vianello@sanita.padova.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento Biomedico di Medicina Interna e Specialistica, Università degli Studi di Palermo</name>
      <address>
        <city>Palermo</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Battaglia, MD</last_name>
      <email>salvatore.battaglia@unipa.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Clinica e Sperimentale, U.O.C. di Clinica Pneumologica, Azienda Ospedaliero-Universitaria di Parma</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alfredo Chetta, MD</last_name>
      <email>alfredoantonio.chetta@unipr.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Medicina Interna e Terapia Medica, Divisione di Malattie dell'Apparato Respiratorio, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Angelo Corsico, MD</last_name>
      <email>corsico@unipv.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. di Riabilitazione Specialistica Pneumologica, Istituti Clinici Scientifici Maugeri SpA - Società Benefit, Istituto di Ricovero e Cura a Carattere Scientifico</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Piero Ceriana, MD</last_name>
      <email>piero.ceriana@icsmaugeri.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dipartimento di Fisiopatologia Respiratoria e Riabilitazione Respiratoria, Dipartimento Cardio-Toracico-Vascolare, Azienda Ospedaliero-Universitaria Pisana</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Federico Dente, MD</last_name>
      <email>f.dente@ao-pisa.toscana.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Unità Operativa Complessa di Pneumologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Richeldi, MD</last_name>
      <email>luca.richeldi@policlinicogemelli.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Struttura Complessa di Pneumologia, Ospedale di Cattinara, Azienda Sanitaria Universitaria Integrata di Trieste ex Azienda Ospedaliero-Universitaria &quot;Ospedali Riuniti&quot; di Tieste</name>
      <address>
        <city>Trieste</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marco Confalonieri, MD</last_name>
      <email>marco.confalonieri@asuits.sanita.fvg.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Hasani A, Chapman TH, McCool D, Smith RE, Dilworth JP, Agnew JE. Domiciliary humidification improves lung mucociliary clearance in patients with bronchiectasis. Chron Respir Dis. 2008;5(2):81-6. doi: 10.1177/1479972307087190.</citation>
    <PMID>18539721</PMID>
  </reference>
  <reference>
    <citation>Rea H, McAuley S, Jayaram L, Garrett J, Hockey H, Storey L, O'Donnell G, Haru L, Payton M, O'Donnell K. The clinical utility of long-term humidification therapy in chronic airway disease. Respir Med. 2010 Apr;104(4):525-33. doi: 10.1016/j.rmed.2009.12.016. Epub 2010 Feb 9.</citation>
    <PMID>20144858</PMID>
  </reference>
  <reference>
    <citation>Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, Murris M, Cantón R, Torres A, Dimakou K, De Soyza A, Hill AT, Haworth CS, Vendrell M, Ringshausen FC, Subotic D, Wilson R, Vilaró J, Stallberg B, Welte T, Rohde G, Blasi F, Elborn S, Almagro M, Timothy A, Ruddy T, Tonia T, Rigau D, Chalmers JD. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017 Sep 9;50(3). pii: 1700629. doi: 10.1183/13993003.00629-2017. Print 2017 Sep.</citation>
    <PMID>28889110</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 25, 2019</study_first_posted>
  <last_update_submitted>October 4, 2021</last_update_submitted>
  <last_update_submitted_qc>October 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>airway warm humidification</keyword>
  <keyword>exacerbation</keyword>
  <keyword>airway clearance</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

